GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kolon Life Science Inc (XKRX:102940) » Definitions » Debt-to-Equity

Kolon Life Science (XKRX:102940) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Kolon Life Science Debt-to-Equity?

Kolon Life Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0 Mil. Kolon Life Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩0 Mil. Kolon Life Science's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩159,690 Mil. Kolon Life Science's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kolon Life Science's Debt-to-Equity or its related term are showing as below:

XKRX:102940' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09   Med: 0.48   Max: 2.05
Current: 0.68

During the past 13 years, the highest Debt-to-Equity Ratio of Kolon Life Science was 2.05. The lowest was 0.09. And the median was 0.48.

XKRX:102940's Debt-to-Equity is ranked worse than
75.59% of 848 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs XKRX:102940: 0.68

Kolon Life Science Debt-to-Equity Historical Data

The historical data trend for Kolon Life Science's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon Life Science Debt-to-Equity Chart

Kolon Life Science Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.78 1.33 0.69 0.44 0.78

Kolon Life Science Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.65 0.65 0.78 -

Competitive Comparison of Kolon Life Science's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Kolon Life Science's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kolon Life Science's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kolon Life Science's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kolon Life Science's Debt-to-Equity falls into.



Kolon Life Science Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kolon Life Science's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Kolon Life Science's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon Life Science  (XKRX:102940) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Kolon Life Science Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kolon Life Science's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Kolon Life Science (XKRX:102940) Business Description

Traded in Other Exchanges
N/A
Address
110, Magokdong-ro, Gangseo-gu, One & Only Tower, Seoul, KOR
Kolon Life Science Inc develops, manufactures and sells Biopharmaceuticals, Active pharmaceutical ingredients, Antimicrobials and Water solutions. Its products include Invossa, KLS-1010, KLS-2020, Azilsartan, Besfloc etc. The company has manufacturing facilities in Chungju, Eumsung and Kimchun.

Kolon Life Science (XKRX:102940) Headlines

No Headlines